<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="40865">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02574390</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00082277</org_study_id>
    <nct_id>NCT02574390</nct_id>
  </id_info>
  <brief_title>Answer ALS: Individualized Initiative for ALS Discovery</brief_title>
  <acronym>AnswerALS</acronym>
  <official_title>Answer ALS -Creation of a Large Bio-repository of iPS Cells, Cell Lines, and Bio-fluid Samples, Combined With Clinical Information to Rapidly Advance Therapeutics That Could Treat ALS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts Institute of Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>New York Genome Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leandro P. Rizzuto Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Creation of a large repository of induced pluripotent stem cells (iPSC), bio-fluid samples
      (blood and spinal fluid (optional)), and cell lines for ALS gene identification. This will
      be combined carefully with collected measures of the pattern of the symptoms people with ALS
      have and how these change over time.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will have 5 study visits; screening, 3, 6, 9 and 12 months. There will be a one
      year post-participation follow-up period, during which they will receive an email or phone
      call interview once every 3 months. During the first year, samples will be collected,
      breathing, muscle strength, spasticity, general function and cognitive behavior will be
      assessed
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>ALS Functional Rating Scale-Revised (ALSFRS-R)</measure>
    <time_frame>once every 3 months for one year</time_frame>
    <description>12 questions about patient's ability to function in certain activities of daily living</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ALS Cognitive Behavioral Scale (ALS-CBS)</measure>
    <time_frame>once every 3 months for one year</time_frame>
    <description>short measure of cognition and behavior in patients with ALS.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Slow Vital Capacity (SVC)</measure>
    <time_frame>once every 3 months for one year</time_frame>
    <description>measurement of the maximum amount of air that can be exhaled following a deep breath.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Strength Testing with Hand Held Dynamometer (HHD)</measure>
    <time_frame>once every 3 months for one year</time_frame>
    <description>muscle strength testing performed on upper and lower limbs, ankles, wrists and fingers using a small hand held device.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <condition>Primary Lateral Sclerosis</condition>
  <condition>Flail Arm ALS</condition>
  <condition>Progressive Muscular Atrophy</condition>
  <condition>Monomelic Amyotrophy</condition>
  <condition>Motor Neuron Disease</condition>
  <condition>Asymptomatic ALS Gene Carriers</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma, serum, DNA, Cerebrospinal fluid, induced pluripotent stem cells,
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients with ALS, Primary Lateral Sclerosis Flail Arm ALS Progressive Muscular Atrophy
        Monomelic Amyotrophy Motor Neuron Disease Asymptomatic ALS Gene Carriers
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants with familial or sporadic ALS diagnosed as possible,
             laboratory-supported probable, probable or definite according to the World Federation
             of Neurology (WFN) El Escorial criteria, Primary Lateral Sclerosis Flail Arm ALS,
             Progressive Muscular Atrophy, Monomelic Amyotrophy, Motor Neuron Disease,
             Asymptomatic ALS Gene Carriers

          -  Participants who are ages 18-100, inclusive.

        Exclusion Criteria:

          -  Participants with Spinal-Bulbar Muscular Atrophy

          -  Known diagnosis of HIV/AIDS, Hepatitis B, or Hepatitis C.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas J Maragakis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James D Berry, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts Generel Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Betsy Mosmiller, BA</last_name>
    <phone>410-502-0495</phone>
    <email>emosmil1@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aiana Rodriguez, BS</last_name>
    <phone>443-287-0627</phone>
    <email>arodri47@jhmi.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peggy Allred</last_name>
      <phone>424-315-2694</phone>
      <email>Peggy.Allred@cshs.org</email>
    </contact>
    <contact_backup>
      <last_name>Dana Fine</last_name>
      <phone>310-423-8497</phone>
      <email>dana.fine@cshs.org</email>
    </contact_backup>
    <investigator>
      <last_name>Robert H. Baloh, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meriada Polak, RN</last_name>
      <phone>404-779-3807</phone>
      <email>mpolak@emory.edu</email>
    </contact>
    <contact_backup>
      <last_name>Anna Partlow, RN, MN</last_name>
      <phone>404-778-3181</phone>
      <email>anna.partlow@emory.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jonathan Glass, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Betsy Mosmiller</last_name>
      <phone>410-502-0495</phone>
      <email>emosmil1@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Aiana Rodriguez</last_name>
      <phone>443-287-0627</phone>
      <email>arodri47@jhmi.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leah Miller</last_name>
      <phone>617-724-7398</phone>
      <email>LMILLER33@mgh.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Maryangel Jeon</last_name>
      <phone>617-724-9196</phone>
      <email>mjeon2@partners.org</email>
    </contact_backup>
    <investigator>
      <last_name>James D Berry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Molly McCallum</last_name>
      <phone>314-362-6159</phone>
      <email>neuroclinicalstudies@neuro.wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Jockel-Balsarotti</last_name>
      <phone>314-362-6159</phone>
      <email>neuroclinicalstudies@neuro.wustl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Timothy Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43221</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ifeanyi Okoh</last_name>
      <phone>614-688-7837</phone>
      <email>ifeanyi.okoh@osumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sharon Chelnick, MHSA, CCRC</last_name>
      <phone>614-293-4973</phone>
      <email>sharon.chelnick@osumc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Stephen J Kolb, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 16, 2016</lastchanged_date>
  <firstreceived_date>October 9, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ALS</keyword>
  <keyword>stem cell</keyword>
  <keyword>biomarker</keyword>
  <keyword>disease progression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Muscular Atrophy</mesh_term>
    <mesh_term>Muscular Atrophy, Spinal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
